AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in ...

The objective of the Fund is to provide a combination of growth and income within a predetermined risk profile. The Fund’s potential gains and losses are likely to be constrained by the objective to ...